Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo 18FTHK5351 uptake in progressive supranuclear palsy

ConclusionsSimilar to AD, the interpretation of [18F]THK5351 uptake in PSP is likely confounded by off-target binding to MAO-B binding sites. [18F]THK5351 is not sufficient in quantifying tau aggregates in PSP using the proposed rasagiline dosing regimen.
Source: NeuroImage: Clinical - Category: Radiology Source Type: research

Related Links:

ConclusionsTherefore, [18F]PI-2620 was selected for clinical validation.
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
Conclusions: The results of this preliminary multi-center evaluation indicate a value of 18F-PI2620 to diagnose and differentiate suspected PSP patients in vivo. The magnitude of tracer binding between patients seems to be variably expressed but not correlated with disease severity. These results indicate that 18F-PI2620 may show potential as a biomarker to assess tau pathology in PSP patients and that it may be helpful to establish earlier and more reliable diagnosis of PSP.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Brain Imaging Council YIA Symposium Source Type: research
Grand Total EEG Score Can Differentiate Parkinson's Disease From Parkinson-Related Disorders Ela Austria Barcelon1,2*, Takahiko Mukaino1, Jun Yokoyama1, Taira Uehara2, Katsuya Ogata2, Jun-ichi Kira1 and Shozo Tobimatsu2 1Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan2Department of Clinical Neurophysiology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan Background: Semi-quantitative electroencephalogram (EEG) analysis is easy to perform and has been used to differentiate dementias, as well ...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
This study aimed to investigate white matter microstructure alterations by using connectometry in patients with PD-EDS, in comparison to PD-nEDS and healthy individuals. Materials and Methods Participants Participants involved in this research were recruited from Parkinson's Progression Markers Initiative (PPMI, http://www.ppmi-info.org/). The study was approved by the institutional review board of all participating sites in Europe, including Attikon University Hospital (Greece), Hospital Clinic de Barcelona and Hospital Universitario Donostia (Spain), Innsbruck University (Austria), Paracelsus-Elena Clinic Kass...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
ConclusionsTau PET tracers have enabled in vivo quantification of PHF-tau burden in human brains. Tau PET can help in understanding the underlying cause of dementia symptoms, and in patient selection for clinical trials of anti-dementia therapies.
Source: Clinical and Translational Imaging - Category: Radiology Source Type: research
Conclusion D2 antagonism by (-)-eticlopride at high dose (0.03 mg/kg) dramatically increased striatal uptake of [18F]VAT in NHPs, suggesting PET with [18F]VAT provides a useful tool for investigation of dopaminergic modulation on VAChT expression in the brain of living animals. The elevation of striatal [18F]VAT uptake by 0.03 mg/kg (-)-eticlopride might be attributed to the disinhibition of cholinergic transmission by D2 antagonism. Ongoing studies are exploring the impact of D2 agonism on VAChT expression in the NHP brain. These results may help guide future investigation of the effects of dopaminergic drugs on cholinerg...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Basic Science III Source Type: research
Conclusions: : Results indicate 18F-PI-2620, a second-generation selective tau tracer, is a sensitive tool to detect tau deposits in the brain. Furthermore, our studies show 18F-PI-2620 is not affected by potentially confounding "off-target" binding.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Imaging Tau and Other Dementia Targets Source Type: research
The cover of this issue relates to one of five articles on tau. Using18F-AV-1451 PET scanning, Merle Hoenig and colleagues report that tau pathology expands along independent pathways that correspond to functional networks known to be impaired in Alzheimer ’s disease, including the default mode network and the frontal control network. Thomas Cope and co-workers also show that highly connected networks are susceptible to tau pathology in Alzheimer’s disease. Such a relationship was, however, not seen in progressive supranuclear palsy, where the bur den appears to correlate instead with increased metabolic demand...
Source: Brain - Category: Neurology Source Type: research
Little is known about Alzheimer's disease molecular proteins, beta-amyloid and paired helical filament (PHF) tau, in progressive supranuclear palsy (PSP). Recent techniques have been developed to allow for investigations of these proteins in PSP. We determined the frequency of beta-amyloid deposition in PSP, and whether beta-amyloid deposition in PSP is associated with PHF-tau deposition pattern, or clinical features.
Source: Parkinsonism and Related Disorders - Category: Neurology Authors: Source Type: research
Objective18F‐flortaucipir (formerly 18F‐AV1451 or 18F‐T807) binds to neurofibrillary tangles in Alzheimer disease, but tissue studies assessing binding to tau aggregates in progressive supranuclear palsy (PSP) have yielded mixed results. We compared in vivo 18F‐flortaucipir uptake in patients meeting clinical research criteria for PSP (n = 33) to normal controls (n = 46) and patients meeting criteria for Parkinson disease (PD; n = 26). MethodsParticipants underwent magnetic resonance imaging and positron emission tomography for amyloid‐β (11C‐PiB or 18F‐florbetap...
Source: Annals of Neurology - Category: Neurology Authors: Tags: Research Article Source Type: research
More News: Alzheimer's | Brain | Neurology | PET Scan | Progressive Supranuclear Palsy | Radiology